John Winikates, MD
Neurology · Columbus, INNPI 1386697712
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 149 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,498 and has fallen 98.9% since, to $17 in 2022. That places this record below the midpoint for neurology clinicians in IN, where the typical reported total is $1,614.
Across 149 payments — averaging $11.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$318
- UCB, Inc.$194
- EMD Serono, Inc.$185
- Biogen$143
- Sanofi$134
- Eisai Inc.$126
- plus $660 from 20 others
What the payments were for
- Food & beverage$1,760100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 30 | $318 |
| UCB, Inc. | 26 | $194 |
| EMD Serono, Inc. | 22 | $185 |
| Biogen | 9 | $143 |
| Sanofi | 8 | $134 |
| Eisai Inc. | 6 | $126 |
| Novartis | 11 | $123 |
| AbbVie(2 entities) | 5 | $81 |
| Pfizer | 3 | $39 |
| Genentech USA, Inc. | 3 | $39 |
| Adamas Pharmaceuticals, Inc. | 3 | $38 |
| Greenwich Biosciences, Inc. | 2 | $37 |
| Acadia Pharmaceuticals Inc | 3 | $35 |
| Amgen | 2 | $32 |
| Livanova USA, Inc. | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 2 | $27 |
| Avanir Pharmaceuticals, Inc. | 2 | $27 |
| Lilly USA, LLC | 2 | $23 |
| Upsher-smith Laboratories LLC | 1 | $23 |
| Harmony Biosciences LLC | 1 | $21 |
| AstraZeneca | 1 | $17 |
| MDD US Operations, LLC | 1 | $17 |
| Aprecia Pharmaceuticals, LLC | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| SK Life Science, Inc. | 1 | $11 |
How this compares
$1,760 in reported general payments places this provider in the 50th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Columbus
- William ConteMerrillville$1.2M
- Anthony SimchakLafayette$720K
- Mark JanickiLebanon$573K
- Ajay GuptaFort Wayne$411K
- Roderick WarrenEvansville$296K
- Ender AkanMunster$296K
- Christopher WilsonAvon$283K
- Marlene BultemeyerFort Wayne$277K
- Jerry SmarttCarmel$254K
- Andrea HallerFort Wayne$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.